Option Care Health Withdraws Its Forecast And Cancels Its Call As Buyout Looms
The infusion provider's third-quarter profit rose to $0.38 a share, but it dropped guidance with Clayton, Dubilier & Rice and McKesson set to buy it.
Option Care Health, the home infusion provider, withdrew its financial guidance and called off its earnings call Wednesday, citing the pending acquisition by Clayton, Dubilier & Rice and McKesson, even as it reported net revenue of $1,493.5 million for the third quarter, up 4.1% from a year earlier.
A quarter of modest gains
Net income under standard accounting was $57.4 million, up 10.8%, or $0.38 per diluted share, up 18.8%. The company has bought back stock, and its diluted share count fell to 150.5 million from 163.1 million a year earlier.
Adjusted EBITDA, the company's profit measure before interest, taxes, depreciation, stock pay and certain other costs, was $124.6 million, up 4.3%. Adjusted diluted earnings per share were $0.49, up 8.9%.
For the first nine months, operating cash flow was $286.2 million, against $222.6 million a year earlier. Cash provided by operations in the third quarter alone was $114.7 million. Cash stood at $299.1 million at September 30, up from $232.6 million at the end of 2025.
No call, no guidance
The company said it has entered a definitive merger agreement under which Clayton, Dubilier & Rice and McKesson will acquire it. Given that pending deal, it will not hold an earnings call and has withdrawn the financial guidance it previously gave.
The deal still depends on stockholder approval and any required regulatory approvals, and the company's risk list includes the possibility that a termination fee could be owed if the agreement ends.
What Option Care does
Option Care Health describes itself as the nation's largest independent provider of home and alternate-site infusion services, delivering medications and nutrition intravenously to patients outside hospitals. According to its latest annual report, it operates 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites.
The company, whose market value was about $4.8 billion at Wednesday's morning report, has more than 8,000 team members, including more than 5,000 clinicians, it said.
Over nine months, net income was $156.7 million, or $1.02 a share, against $149.1 million, or $0.91, a year earlier.
Sources
- 8-K Filing — Option Care Health, Inc. (OPCH) — SEC EDGAR
- Exhibit exhibit991-q32026.htm — Option Care Health, Inc. 8-K exhibit — SEC EDGAR